Synergy of two drugs may treat imatinib-resistant chronic myeloid leukemia
Danusertib and bosutinib work together to overcome resistance to imatinib for chronic myeloid leukemia (CML) with mutated BCR-ABL gatekeeper genes. The BCR-ABL mutation confers resistance to all currently approved kinase inhibitors for chronic myeloid leukemia.
